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Abstract 
Abnormalities in fatty-acid metabolism are believed to play a role in nonspecific acute encephalopathy (AE) with hepatomegaly, 
although the specific nature of these abnormalities and their temporal relationship to the pathology are not well defined. We have 
examined hepatic fatty-acid /3-oxidation and metabolism in a mouse model for AE in which neonatal mice were exposed ermally to 
nontoxic doses of the industrial surfactant, Toximul MP8 (Tox), daily from days 1 to 12 after birth, and then infected with a sublethal 
dose (LD3o) of mouse-adapted human influenza B (Lee) virus (FIuB). The number of deaths in the group treated with Tox + FluB were 
significantly higher than those in the group infected with virus alone. Under optimal in vitro assay conditions, /3-oxidation of 
[1-14C]palmitic acid was = 15% higher in liver homogenates from mice painted with Tox for 12 days (P<0.02);  catabolism of 
[1-14C]octanoic a id to t4C-labelled water-soluble products (|4C-WSP) and 14CO2 was unaltered by Tox. Infecting Tox-free mice with 
FluB inhibited /3-oxidation of both [1-~4C]palmitate and [l-lZC]octanoate by 20-30% (P<0.001). On days 18-19, when most 
Tox + FluB-dependent deaths occurred, the inhibition of oxidation was increased to = 50% in mice given the combined treatment. 
Treatment of the mice with Tox/FluB also altered the pattern of incorporation of fatty acids into complex lipids. Hepatic levels of 
thiobarbituric acid reactive substance (TBARS), a marker for lipid peroxides, were = 15% higher in Tox-painted than in control mice 
(P < 0.01); FluB alone had no effect. In Tox + FluB-treated animals, TBARS levels were > 2-fold higher than in any other experimental 
group (P < 0.001). These studies demonstrated that nasally-administered FIuB has profound effects on hepatic fatty-acid metabolism, 
particularly /3-oxidation. Exacerbation of this and related effects by exposing young animals to xenobiotic surfactants could be the basis 
of surfactant-mediated potentiation of virus-induced mortality. 
Keywords: Fatty-acid /3-oxidation; Palmitic acid; Octanoic acid; Reye's syndrome; Influenza B virus; Surfactant; Acute hepatic encephalopathy; (Mouse 
liver) 
1. Introduction 
One example of a nonspecific acute encephalopathy 
(AE) with hepatomegaly is Reye's Syndrome (RS), a rare 
but often fatal childhood disorder of unknown etiology. 
When it occurs, it frequently (> 80%) follows a 
relatively-benign viral illness such as influenza or varicella 
Abbreviations: AE, nonspecific acute encephalopathy with hep- 
atomegaly; BSA, bovine serum albumin; FluB, mouse-adapted human 
influenza B (Lee) virus; ITLC, instant hin-layer chromatography; MEM, 
minimal essential medium; RS, Reye's syndrome; Tox, toximul; WSP, 
water-soluble products; TBARS, thiobarbituric-acid-reactive substances. 
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[1], and is believed by many to involve an exogenous toxin 
or cofactor, although no single agent has been identified 
unequivocally [2-4]. The hepatic and cerebral dysfunctions 
that dominate the clinical picture include hepatic mito- 
chondrial damage, fatty infiltration of the liver, abnormal 
serum lipid profiles, hyperammonemia and highly-elevated 
intracranial pressure with severe brain edema (for review, 
see Refs. [4,5]). Several ines of evidence suggest hat the 
disease involves disturbances in hepatic fatty-acid /3- 
oxidation, including observations that patients have high 
serum levels of free fatty acids and dicarboxylic acids, 
elevated levels of short- and medium-chain fatty acyl-CoA 
derivatives and branched-chain amino acids [6], as well as 
compromised leukocyte oxidation of [~4C]octanoic acid 
[7]. 
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Little is known regarding the effects of a viral infec- 
tions on fatty-acid oxidation, and even less about whether 
exposure to chemical(s) modifies any virus-induced ef- 
fects. However, it is of considerable interest hat at least 
some of the chemicals that have been associated with RS, 
or that produce an RS-like illness, are known inhibitors of 
this important metabolic process [8,9]. 
We have developed and characterized a chemical/virus 
animal model for AE that affords an excellent opportunity 
to investigate this issue. It involves painting neonatal mice 
with nontoxic doses of the industrial surfactant, Toximul 
MP8 (Tox), daily for 12 days, and then infecting the 
animals intranasally with sublethal (LD30) amounts of 
mouse-adapted human influenza B (Lee) (FIuB) [10,11]. 
The combined treatment produces many of the features of 
human RS, including, hyperammonemia [11], elevated in- 
tracranial pressure [12] and a high mortality rate [11-13]. 
There is hepatic mitochondrial dysfunction associated se- 
lectively with the Tox + FluB treatment, as judged by 
severe ultrastructural bnormalities in the organelles and 
significantly reduced activity of the urea cycle enzyme, 
ornithine transcarbamylase (OCT, carbamyl phosphate:L- 
ornithine carbamyl transferase; EC 2.1.3.3) [11]). Consid- 
erable abnormalities in intermediary lipid metabolism are 
suggested by dramatic hanges in serum [14] and hepatic 
[15] lipid/fatty-acid profiles in the Tox + FluB mice. In 
preliminary studies, we observed that, in vitro, the addition 
of Tox to the assay inhibited hepatic oxidation of [1- 
14C]palmitic acid and altered its pattern of incorporation 
into complex lipid (unpublished ata). However, we can- 
not assume that chronic dermal application of Tox would 
produce the same effect(s); also, only through the use of 
the in vivo paradigm could we assess reliably the effects of 
virus (and its interaction with surfactant) on 13-oxidation. 
Accordingly, the purpose of the present study was to 
determine the effects of dermal exposure to Tox, FluB 
infection and the combined treatment on fatty-acid 13- 
oxidation and metabolism in livers of neonatal mice. 
2. Materials and methods 
2.1. Materials 
[l-14C]Palmitic acid (spec. act. 56 mCi/mmol) and 
[1-14C]octanoic acid (spec. act. 53.5 mCi /mmol)were 
obtained from Dupont Canada (Mississauga, Canada). 
Palmitic acid and other lipid standards were from Serdary 
Research Laboratories (London, Canada). ATP, L-carni- 
tine, coenzyme A, dithiothreitol, fatty-acid-poor BSA, 
thiobarbituric acid and l,l,3,3-tetraethoxypropane were 
purchased from Sigma Chemicals (St. Louis, MO). What- 
man glass microfibre paper (GF/B) was from Fisher 
Scientific (Dartmouth, Canada), and the polysilicic acid 
gel-impregnated glass fibre sheets used for instant thin- 
layer chromatography were purchased from Gelman Sci- 
ences (Montreal, Canada). FIuB was originally obtained 
from Dr. Frank Ennis, National Institutes of Health, 
Bethesda, MD. Toximul MP8 (Tox, Lot 9-30162) was 
from Charles Tenant, Toronto, Canada. 
2.2. The surfactant / FluB mouse model 
The surfactant/virus mouse model for RS has been 
described in detail elsewhere [11]. Briefly, male and fe- 
male Swiss Webster (ND4) white mice were mated and the 
mothers were allowed to deliver. Mice born on the day in 
which the largest number of births occurred were pooled 
and were randomly divided into groups of nine pups per 
nursing mother. Twenty-four hours later, the pups were 
divided arbitrarily into two groups; minimal essential 
medium (MEM) was applied dermally to the abdomens of 
the first group, while the other group was painted with the 
commercial industrial surfactant, Toximul MP8 (Tox) di- 
luted in MEM (1%, by vol.). This treatment was repeated 
daily for 12 days. For the first 5 days, the mice received 
8.6 _+ 2.6 mg Tox per day; this dosage was increased to 
25.8 _+ 9.0 mg per day for the last 7 days. On day 13. half 
of each of the MEM and Tox groups were given 10 /zl of 
mouse-adapted human influenza B (Lee) virus (FIuB) (640 
HA units/0.5 ml) intranasally under light ether anaesthe- 
sia; the other half of each group received anaesthetic alone. 
Deaths were recorded each morning throughout the experi- 
ment. All studies were carried out with the approval of the 
Canadian Council on Animal Care. 
2.3. Homogenate preparation 
At different times during both the painting and post-virus 
periods, 3-6 mice were taken from each group and were 
killed by decapitation. The livers were excised immedi- 
ately in ice-cold modified Krebs-Henseleit bicarbonate 
buffer (pH 7.4) that contained (in mM): NaCl (111), KC1 
(4.7), MgSO 4 (2), NaH2PO 4 (1.2), NaHCO 3 (26.2) and no 
Ca 2+. This solution was gassed with 02 :CO 2 (95:5, vol:vol) 
for at least 20 min, after which MgCI 2 and glucose were 
added at final concentrations of 2.4 and 11 mM, respec- 
tively. Homogenates (1-2%, w/v)  were prepared using 6 
strokes of a glass-teflon homogenizer, and were used 
immediately for the assays, since previous experiments had 
shown that 13-oxidation activity was reduced by > 80% in 
preparations that were stored at -70°C (data not shown). 
Protein was determined using the method of Lowry et al. 
[16], using bovine serum albumin (BSA) as a standard. 
2.4. Fatt3'-acid oxidation assay 
[1-~4 C]Palmitic acid oxidation was measured essentially 
as described by Mannaerts et al. [17], and modified by 
Murphy et al. [ 18]. Unless indicated otherwise, the reaction 
mixture contained, in a final volume of 150 /,~1 of modified 
Krebs-Henseleit buffer (see above): 0.2 mM [1- 
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14C]palmitic acid (4000-5000 dpm/nmol) bound to fatty- 
acid-poor BSA in a 3:1 molar ratio, 1 mM ATP, 2 mM 
dithiothreitol, 0.5 mM L-carnitine, and 0.05 mM coenzyme 
A (CoA). The reaction mixture was put in the bottom of a 
1.5 ml polypropylene tube that was placed in a 20 ml 
screw-cap glass liquid scintillation vial. A small disc (8 
mm diameter) of GF /B  glass fibre paper saturated with 80 
/~1 of hyamine hydroxide (1 M) in methanol was placed on 
the bottom of the glass vial away from the reaction tube. 
The reactions were initiated by the addition of 50 /zl of 
liver homogenate (= 50 /xg protein), and the vials were 
tightly capped and incubated at a 45 ° angle in a shaking 
water bath (37°C) for 5 min. We determined previously 
that the fatty-acid and protein concentrations, and the 
incubation time were optimal for this in vitro assay (un- 
published); we also recognize that this process is unlikely 
to function at maximal rates in vivo. The reactions were 
terminated by the addition of 20 /zl of HCIO 4 (70%, by 
vol.), and the vials were quickly recapped and allowed to 
equilibrate for 30 min at room temperature. The tubes were 
removed from the glass vials, liquid scintillation cocktail 
was added, and radioactivity was counted for measurement 
of 14CO 2 formation. The contents of the polypropylene 
tubes were extracted with chloroform/methanol (2:1, v/v) ,  
and samples of the aqueous and organic phases were 
counted for measurement of water-soluble and lipid prod- 
ucts, respectively. Total /3-oxidation (mitochondrial plus 
peroxisomal) is expressed as the sum of 14CO2 and 14C- 
water soluble products (WSP) generated. Peroxisomal /3- 
oxidation was estimated several times during the experi- 
ment by carrying out the assays in the presence of 2 mM 
KCN which is known to block mitochondrial /3-oxidation 
[17]; the contribution of the mitochondrial process was 
assessed indirectly, by subtracting peroxisomal from total 
/3-oxidation. These assays were extended to 30 min in 
order to maximize inhibition; accordingly, the rate of 
substrate oxidation was less than that obtained under opti- 
mal conditions. 
The assay for [1-14C]octanoic acid oxidation was car- 
ried out using essentially the same conditions as those 
described above, except hat 60-90 /.tg protein was added. 
After incubation with 0.2 mM [1-J4C]octanoic acid, chlo- 
roform/methanol (2:1, v /v )  was added to the reaction 
mixture to form two phases. The aqueous phase (0.4 ml) 
was extracted twice with 1.33 ml of n-hexane. It has been 
demonstrated that the hexane removes more than 98% of 
[1-14 C]octanoic acid without removing ketone bodies and 
other water-soluble products [8,19]. Duplicate samples of 
the aqueous phase were counted for 14C-WSP. 
2.5. Quantitation of ATP 
Levels of ATP were quantitated in liver homogenates 
using a kit from Sigma (catalogue No. 366). 
2.6. Incorporation of [1-14C]palmitate and [1-14C]oc - 
tanoic acids into complex lipid 
The chloroform phases were dried under N 2, spotted on 
silicic-acid-impregnated chromatography papers, and the 
chromatograms were developed in a solvent system of 
petroleum ether/diethyl ether/acetic acid (90:10:1, by 
vol.). Spots that co-chromatographed with authentic stan- 
dards were cut out and counted for quantitation of 
phospholipids, triglycerides, free fatty acids and choles- 
terol esters. 
2.7. Measurement of hepatic levels of thiobarbituric-acid- 
reactit, e substances 
Lipid peroxidation was assessed as the amount of thio- 
barbituric-acid-reactive substances (TBARS) in liver ho- 
mogenates following formation of a color product, essen- 
tially as described by Ledwozyw et al. [20]. Aliquots of 
liver homogenates (0.5 ml) were acidified with trichloro- 
acetic acid (5%, w/v ;  0.75 ml), and the mixtures were 
reacted with 0.25 ml of 0.6% (w/v)  thiobarbituric acid in 
capped tubes at 100°C for 60 min. The boiled samples 
were cooled and then centrifuged at 3000 rpm for 10 min. 
Samples were read at 532 nm on a Beckman DU-64 
spectrophotometer. 1,1,3,3-Tetraethoxypropane was used 
as the standard. 
2.8. Statistical analysis 
Mortality data were analyzed using the Kaplan-Meier 
product moment method, and differences between the sur- 
vival curves were tested by using the Mantel-Haenszel 
summary ~2 procedure as described previously [11]. Bio- 
chemical data were analyzed using a Student's t-test. 
Differences were considered significant when the value for 
P was less than 0.05. 
3. Results 
3.1. Mortalit3, 
Mortality data from a representative experiment are 
shown in Fig. 1. In this experiment, several mice in the 
control (MEM) group died during the initial painting part 
of the experiment. This was an unusual occurrence, and 
one that is not readily explainable; we believe that it was 
related to inattentiveness on the part of a nursing mother, 
which is not uncommon in mouse colonies. In the groups 
painted with MEM or Tox and then infected with FluB, 
deaths first occurred on day 15, two days following virus 
inoculation. On day 16, the number of deaths in the 
Tox + FluB group began to increase relative to that in the 
FluB alone group. The maximum number of deaths were 
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Fig. I. Cumulative mortality rates in the mouse model for Reye's 
Syndrome. Neonatal mice were painted daily for 12 days with MEM or 
Tox (1%, by vol_ in MEM). The doses are given in Section 2. On day 13, 
half of the mice from each group received intranasal inoculations of 
Influenza B (Lee) Virus (FluB) under light ether anesthesia. The other 
half received anesthesia alone. Deaths were recorded aily. The data are 
from a representative experiment: they indicate the percentage of animals 
that died in each of the four treatment groups during each 24-h period 
following virus inoculation and/or anesthesia. The numbers in parenthe- 
ses indicate the number of mice in each group, 
recorded between 18-20 days, at which time 42% of the 
mice in the FluB group and 78% of those given Tox + FIuB 
had died. Differences between the mortality rates in these 
two groups were highly significant as judged by Mantel- 
Haenszel analysis (P  < 0.0001). 
3.2. jg-oxidation of [1-14C]palmitic acid." effects of Tox 
and/or FluB 
Under optimal assay conditions (= 50 /xg protein, 0.2 
mM [l-HC]palmitic acid, 5 rain incubation), liver ho- 
mogenates from 11- and 12-day-old untreated mice cat- 
alyzed the formation of 21.4_+0.8 nmol [14CO2+ 
l~WSP]/min/mg protein (mean + S.D., n = 6) from [1- 
HC]palmitic acid. Less than 0.5% of the total product was 
released as ~4CO2 (data not shown). Eadie-Hofstee analy- 
sis of data from four assays in which the substrate concen- 
tration was increased from 0.025 to 0.8 mM indicated 
apparent values for Vm, × and S05 of 32.8 _+ 2.4 
nmol /min /mg protein and 0.14_+0.03 mM (mean+_ 
S.D.), respectively, 
Total /3-oxidation of [1-~4C]palmitic acid by the liver 
homogenates was measured at intervals throughout he 
experiment. During the painting period, there was an age- 
dependent increase in oxidation until rates reached a maxi- 
mum around day 12; thereafter they declined (Fig. 2). 
Mice that were painted with Tox for > 8 days oxidized 
[ 1-~4C]palmitate at rates that were significantly higher than 
those of the controls (P < 0.02-0.001). On days 16-19 of 
the experiment, formation of ~4CO~ and ~'~C-WSP from 
[1-14 C]palmitate by liver homogenates from Tox-free mice 
that had been infected with FluB was 20-30% lower than 
that in the MEM or Tox groups (P  < 0.02-0.001). On day 
19, oxidation of [1-J~C]palmitate was inhibited by > 50% 
in the Tox + FluB group, which represented a potentiation 
of the effect seen with mice infected with FluB alone 
(P  < 0.001). By day 21, the rates of palmitate oxidation in 
the Tox + FluB remained low compared to all other exper- 
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Fig. 2. The effects of dermal Tox exposure and FIuB infection on the total /3-oxidation of [l-14C]palmitic acid by homogenates of liver from neonatal 
mice. The mice were painted with MEM (control) or Tox daily for 12 days. On day 13, half of each of the MEM and Tox groups was infected by FIuB 
intranasally. The other half of each group was exposed to light ether anaesthesia alone. Total /3-oxidation of [l-]4C]palmitic acid (0.2 raM) by liver 
homogenate (30-60 ~g protein) was determined by measuring the products (J4CO2 + 14C-water soluble products) formed during a 5-rain incubation as 
described in Section 2. Values are means + S.D. of values obtained from 3-10 separate mice. ~ P < 0.02, b p < 0.01, ~ P < 0.001, relative to values in the 
MEM group; d p < 0.01, ~ P < 0.001, relative to values in the Tox group; ¢ P < 0.001, relative to values in the FluB group. 
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Fig. 3. Effects of Tox and FIuB on (A) KCN-sensitive (mitochondrial) and (B) KCN-insensitive (peroxisomal) /3-oxidation of [l-]4C]palmitic acid. 
Neonatal mice were exposed to MEM or Tox and subsequently infected with FluB or light ether anaesthesia asdescribed in Section 2 and in the legend to 
Fig. 1. The assays were carried out with 0.2 mM [l-14C]palmitate and 30-60 /xg liver homogenate protein for 30 min in the absence (total oxidation) or in 
the presence of 2 mM KCN. The difference between the two values was interpreted as representing mitochondrial (KCN-sensitive) /3-oxidation. The data 
are means + S.D. of values obtained with 3-5 different mice. a p < 0.05, b P < 0.02, relative to values for the MEM group. ~ P < 0.01, relative to values 
with the Tox group. 
imental groups; however, the differences were significant 
only relative to values obtained in the MEM and the 
Tox-painted groups (P < 0.01). 
3.3. Effects of Tox and~or FluB on mitochondrial and 
peroxisomal [3-oxidation of [I- J4 C]palmitate 
Several experiments were carried out to assess whether 
there was any apparent selectivity in the effects of Tox 
and/or FIuB toward peroxisomal relative to mitochondrial 
oxidation. The assays were carried out in the absence or 
presence of 2 mM KCN, which estimates total and peroxi- 
somal oxidation, respectively [17]; mitochondrial oxidation 
is taken as the difference between the two values. The data 
from these studies, which we recognize as being only a 
rough estimate that measures only the first cycle of peroxi- 
somal oxidation, suggested that mitochondrial oxidation 
was inhibited following FluB infection (Fig. 3A), while 
Tox alone appeared to increase the peroxisomal process 
(Fig. 3B). These apparent organelle-specific effects will be 
investigated in detail in the near future. 
3.4. B-Oxidation of [1-14C]octanoic acid." effects of Tox 
and/or FIuB 
Initial studies indicated that homogenates of livers from 
12-day-old mice catalyzed formation of 16.2 __+ 0.5 nmol 
[14CO 2 + 14C-WSP]/min/mg protein (mean ___ S.E., n = 
6) from 0.2 mM [l-14C]octanoic acid. Analysis of data 
from 3 separate saturation experiments indicated apparent 
values for Vma x and S0. 5 for octanoate of 17.6 +4.9 
nmol /min /mg protein and 0.15 ___ 0.08 mM, respectively. 
Its oxidation exhibited a developmental pattern that was 
similar to that for palmitate, namely, a gradual increase 
after birth with a maximum around day 12 (Fig. 4). 
However, unlike the situation with palmitate, Tox painting 
alone had no apparent effect on the formation of [14CO2 
+14C-WSP] from [1-~4C]octanoate. Oxidation rates in 
Tox-free mice that were infected with FluB were approx. 
30% lower than those in control animals (P  < 0.001), and 
inhibition was exacerbated byprior Tox painting (P  < 0.02, 
relative to FluB alone). 
3.5. Effects of Tox and/or HuB on hepatic lec, els of ATP 
Hepatic levels of ATP were determined on days 4, 8, 12 
and 18 of the experiment. Prior to infection with FluB, 
levels averaged 2.24 + 0.03 /xmol/g wet wt. liver (mean 
± S.D.); there were no differences between values in the 
MEM and Tox groups. On day 18, five days after inocula- 
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Fig. 4. Effects of Tox and FIuB on total /3-oxidation of [l-HC]octanoic 
acid. Neonatal mice were painted with MEM or Tox and subsequently 
infected with FluB or light ether anaesthesia asdescribed in the legend to 
Fig. 1. The /3-oxidation rate was determined by measuring the total 
amount of product (14CO 2 + lnc -wsP)  formed from [l-14C]octanoic 
acid by homogenates of livers from mice in each experimental group. The 
assays were carried out with 0.2 mM [l-tZC]octanoic acid and 60-70 /~g 
homogenate protein for 5 min, and products were separated as described 
in Section 2. The data are means +S.D. of values obtained from 3-8 
different mice. a p < 0,001,  relative to values in the MEM group b p < 
0.001, relative to values in the Tox group c p < 0.02, relative to values in 
the FIuB group. 
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tion, the values were 2.18 + 0.15, 2.17 ___ 0.17, 2.00 + 0.16 
and 1.74 + 0.21 for the MEM, Tox, FIuB and Tox + FluB 
groups respectively. Analysis indicated that differences 
were statistically significant between MEM or Tox versus 
the Tox + FIuB groups (P  < 0.05). 
3.6. Effects of Tox and/or FluB on the incorporation of 
[1-/4 C]palmitate and [1-/4 C]octanoate into complex lipid 
On day 16 of the experiment, homogenates of liver 
from mice that had been either exposed ermally to Tox or 
infected with FIuB incorporated more [1-~4C]palmitic a id 
into phospholipid than did control homogenates (Fig. 5A). 
Neither treatment altered the amounts of [1-14C]octanoic 
acid esterified to this lipid class (Fig. 5B). By comparison, 
FluB infection alone increased by > 30 and > 40% the 
amounts of [1-14C]palmitate (P<0.02)  and [1-~4C]oc - 
tanoate( P < 0.01 ), respectively, that were incorporated into 
triacylglycerol (Fig. 5). Formation of cholesterol esters of 
the [~4C]fatty acids was similar in all treatment groups; in 
no case was there an appreciable amount of radioactivity 
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Fig. 6. Effects of Tox and FluB on hepatic levels of thiobarbituric-acid- 
reactive substances (TBARS). Liver homogeuates were acidified with 
trichloroacetic acid and reacted with thiobarbituric acid as described in 
Section 2. Samples were read at 532 nm and TBARS levels were 
quantitated using 1,1,3,3-tetraethoxypropane s the standard. The data are 
means_S.E, of values obtained from analyses of 3-5 different mice. 
P < 0.01, b p < 0.001, relative to values in the MEM group; c p < 0.001, 
relative to values in the Tox group; ~ P < 0.01. relative to values in the 
FIuB group. 
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Fig. 5. Effects of Tox and FIuB on the incorporation of (A) [ 1-14 C]palmitic 
and (B) [1-14C]octanoic acids into 14C-labelled phospholipid and triglyc- 
eride. Neonatal mice were exposed to MEM or Tox and subsequently 
infected with FIuB or exposed to light ether anaesthesia asdescribed in 
Section 2 and in the legend to Fig. 1. The /3-oxidation assays were carried 
out with 0.2 mM [1-14C]fatty acids and the optimum amounts of liver 
homogenate protein (see Section 2). After the 5 min incubation, the 
reaction mixtures were extracted with chloroform/methanol (2:1, by vol.) 
and additionally, with hexane for octanoate, and the lipids in the organic 
phases were separated on instant TLC as described in Section 2, Areas 
corresponding to authentic standards were counted for quantitation of 
each lipid class. The data represent means + S.E. of values obtained from 
4-7 different mice. a p < 0.02, b p < 0.01, ~ P < 0.001, relative to values 
in the MEM group; a p < 0.01, e p < 0.001, relative to values in the Tox 
group. 
that co-chromatographed with free cholesterol (data not 
shown). 
3. 7. Hepatic levels of TBARS 
Since data from the oxidation studies suggested that 
dermal Tox painting results in stimulation of peroxisomal 
/3-oxidation, and a by-product of this pathway is H202, we 
measured hepatic levels of TBARS, which provide at least 
a crude estimate of the lipid peroxidation status of the 
tissues. As is shown in Fig. 6, values obtained with 
homogenates of mice treated with Tox alone tended to be 
slightly higher than those from MEM-painted mice. By 
comparison, levels of TBARS in liver homogenates from 
mice given the combined Tox + FluB treatment were >_ 2- 
fold higher than those in any of the other experimental 
groups (P  < 0.01-0.001). 
4. Discussion 
Hepatic fatty-acid oxidation plays an indispensible role 
in energy metabolism, particularly in neonatal animals [21] 
and with fasting [22], as it is essential for maintaining a
high rate of gluconeogenesis and for production of ketone 
bodies [23]. It is a highly complex process that requires the 
concerted actions of many different enzymes that function 
in mitochondria [24] as well as peroxisomes [25]. The level 
of complexity affords many different argets and means by 
which the process can be altered. As such, it is not 
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surprising that there is a rapidly-growing list of disease 
states that appear to involve disturbances in the /j-oxida- 
tion pathway. 
The first noteworthy observation from this study was 
that homogenates of liver from mice that had been painted 
with Tox for 12 days produced 14CO2 and 14C-WSP from 
[1-14C]palmitic acid at significantly higher rates than did 
those from age-matched (MEM-painted) controls (Fig. 2). 
This may be due to enhanced peroxisomal numbers or 
activities, as suggested by the approximate 50% increase in 
KCN-insensitive oxidation (Fig. 3B). Confirmation of this 
requires additional study, such as direct measurement of
acyl-CoA oxidase activity. We believe that it would not be 
unreasonable, since many xenobiotic hydrocarbons, includ- 
ing industrial surfactants [26,27], have been shown to 
increase peroxisomal oxidation. Most of these, like Tox, 
are carboxylic acids, or are catabolized to carboxylic acids 
in vivo. Tox is a complex mixture of anionic and nonionic 
surfactants, with the major components being dodecylben- 
zene sulfonate (anionic) and a nonylphenol ethoxylate of 
polyethylene glycol (nonionic) [28]. The anionic form 
exists as branched-chain or linear species that contain 
11-13 or 8-9 carbon atoms, respectively, in the n-alkyl 
chain [29]. In vivo studies demonstrated that they are 
partially degraded by a series of to- and /j-oxidation steps, 
with production of variable-length sulfophenyl carboxylic 
acids [29]. The effects of chronic exposure to these com- 
pounds on organelle structure and/or function are not well 
understood. Our earlier morphological studies showed that 
mice exposed to Tox had mitochondria that were slightly 
enlarged and pleomorphic, but had near-normal matrices 
and cristae [11,30]. There was also an apparent increase in 
the number of peroxisomes in these animals; however, we 
have not quantitated this effect (unpublished observations). 
Other data suggested that Tox application has significant 
effects on hepatic metabolism even though there is no 
apparent 'clinical' toxicity (i.e., mortality). For example, 
chronic exposure results in transient elevations in serum 
ammonia [11] and liver lipid [15] levels and in liver 
weights (increased = 30% on days 6 and 12, unpublished 
data), as well as in increased levels of TBARS (Fig. 6). It 
was interesting to find that formation of 14CO 2 and HC- 
WSP from [1-14C]octanoate, he 8-carbon fatty acid that 
has been implicated in RS [31], was the same as that in 
MEM-painted animals (Fig. 4). This would be consistent 
with a concept hat octanoate is catabolized primarily by 
the mitochondria in the young mice, while the first cycle 
of [1-14C]palmitate oxidation, which is reported to be 
primarily peroxisomal [32], is sensitive to Tox treatment. 
Assays carried out with mice that were only infected 
with FluB (i.e., Tox-free) demonstrated that the formation 
of 14CO2 and 14C-WSP from [1-14C]palmitate was signifi- 
cantly reduced three days after inoculation, and that this 
effect persisted for at least three days (Figs. 2 and 3). 
Assays with [1-14 C]octanoate indicated that its catabolism 
was also inhibited (Fig. 4). Previous investigations have 
demonstrated that effects of viruses on lipid metabolism, 
and vice versa, are extremely complex, are dependent upon 
the nature of both host and virus, and can vary with the 
route of administration. For example, findings may be very 
different depending on whether the studies are done fol- 
lowing in vivo infection or with infected cultured cells 
[33]. The many reported effects include inhibition of 
cholesterol synthesis [33], altered proportions of specific 
membrane fatty acids [34], and increased as well as de- 
creased neutral and polar lipid synthesis [35,36]. With 
respect o complex lipid synthesis, the present study indi- 
cated that, in general, FluB infection enhanced the incor- 
poration of fatty acid into triglyceride, and in the case of 
palmitate, also into phospholipid (Fig. 5). This can be 
explained by an increased availability of fatty acid due to 
inhibition of /J-oxidation; its inhibition has also been 
reported to increase ndogenous cholesterol synthesis [37], 
which we would not detect in these short assays, but did 
observe in earlier studies [15]. There have been very few 
studies of the effects of virus infection on fatty-acid oxida- 
tion. In one, Grossberg et al. concluded that infecting chick 
embryos with West Nile virus did not affect hepatic fatty- 
acid oxidation; however, this was based only on formation 
of ~4CO2 from J4C-labeled oleic acid, and did not consider 
the major 14C-WSP components [38]. More recently, 
Trauner et al. reported that J4CO2 production from palmitic 
acid was reduced by = 40% in mitochondria from mice 
given bolus i.v. doses of FluB [39]. It is difficult to 
compare their data to ours, since they also did not deter- 
mine the effects on the formation of 14C-WSP. Moreover, 
it is known that i.v. administration of virus produces liver 
lesions [40], and structural damage itself could directly 
affect the oxidation process. The intranasal route that we 
use does not alter liver morphology appreciably [11], which 
suggests that FIuB does not exert its inhibitory effects on 
r-oxidation by an obvious physical alteration in hepatic 
structure. Moreover, observations that our FluB-infected 
mice had normal hepatic OCT activities [11] and TBARS 
levels (Fig. 6), and serum ammonia levels [11] support he 
suggestion that by itself, the virus did not result in general- 
ized hepatic dysfunction. 
The primary aim of this study was to identify one or 
more biochemical parameter(s) that distinguished, qualita- 
tively or quantitatively, the mice given the combined treat- 
ment from those given FluB alone. We believe that this 
has been achieved with the demonstration that both palmi- 
tate (Fig. 2) and octanoate (Fig. 4) oxidation were inhib- 
ited in the Tox + FluB-treated mice to a significantly 
greater extent than in the group exposed to FluB alone 
(P  < 0.001 and 0.02, respectively). Very interestingly, this 
occurred on the day when the difference between the 
number of deaths in the Tox + FluB and FluB alone 
groups was the greatest (Fig. 1). As well, only livers from 
the Tox + FIuB group had significantly elevated levels of 
TBARS (Fig. 6), which led us to believe that lipid per- 
oxidation may be involved; they also had the lowest levels 
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of ATP (Section 3.5.). The latter is consistent with reports 
that there are decreases in cellular ATP concomitant with 
inhibition of fl-oxidation [41]. This was also the tendency 
in the endotoxin (LPS)+ ASA (acetyl salicylic acid) rat 
model for RS of Kilpatrick et al. [42]. On the basis of 
reductions in hepatic levels of ketone bodies, these authors 
reported that fatty-acid oxidation was inhibited in the 
combined treatment group relative to rats treated with 
ASA alone. However, their findings differ from ours in the 
respect that they did not observe significantly greater 
inhibition of /3-oxidation in their ASA + LPS group rela- 
tive to that given LPS alone. Thus, only our studies have 
shown chemical potentiation of a metabolic disturbance 
triggered by an infectious agent. Chemical-mediated exac- 
erbation of insults due to a virus infection is not unprece- 
dented [43-47]. Nonsteroidal anti-inflammatory agents, 
such as salicylates, indomethacin and/or acetaminophen, 
have been reported to potentiate mortality and pathology in 
mice infected with a variety of viruses, including influenza 
B [43,44] and encephalomyocarditis (EMC) [45], and in 
humans, to prolong illness due to varicella [46] and rhi- 
novirus [47]. In a rare study with industrial surfactants 
[45], Hug et al. demonstrated that intramuscular injection 
of Atlox, which is similar in composition to Tox [28], 
potentiated liver pathology in EMC-infected mice. On the 
basis of the known metabolic pathways of all of these 
xenobiotic agents, including the abilities of at least some to 
sequester intracellular coenzyme A [8,9,48], it is tempting 
to speculate that they could share one or more common 
mechanisms that constitute the basis of the chemical/virus 
interaction. These could include virus-enhanced production 
of toxic metabolites of the chemical, blockade of their 
degradation/removal, or increased sensitivity to these 
'toxins' [6]. If they accumulate in sufficient quantities they 
could inhibit mitochondrial /3-oxidation at enzymatic steps 
distinct from those affected by FluB. Studies have shown 
that xenobiotic arboxylic acids or their CoA derivatives 
have the capacity to inhibit a variety of enzymes including 
palmitoyl-CoA ligase [49], carnitine palmitoyltransferase I 
[50], and 3-ketoacyl-CoA thiolase [51]. Clearly, we must 
determine the specific step(s) at which the virus inhibits 
oxidation before we can determine whether multi-enzyme 
inhibition underlies the potentiation phenomenon. As well, 
clarification of the role of tissue peroxidation i  the pro- 
cess, and elucidation of the effects of the individual and 
combined treatments on factors that protect against oxida- 
tive damage (e.g., catalase, vitamins), should contribute to 
our understanding of the mechanism(s) involved. 
To our knowledge, this is the first study that has shown 
that infection with a respiratory virus has dramatic effects 
on hepatic lipid metabolism. It has also demonstrated that 
prior (and possibly concurrent) exposure to a relatively 
innocuous chemical has the potential to exacerbate these 
effects in a manner that could lead to more widespread 
metabolic and structural damage. Ultimately, events may 
be triggered that affect extrahepatic organs, particularly 
brain. The specific mechanisms underlying all of these 
abnormalities remain to be determined. 
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